Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec;14(12):44-48.

Prognostic Biomarkers in Melanoma: Tailoring Treatments to the Patient

Bijan Safai  1   2 , Albert G Wu  1   2 , Carl V Hamby  1   2
Affiliations
Review

Prognostic Biomarkers in Melanoma: Tailoring Treatments to the Patient

Bijan Safai et al. J Clin Aesthet Dermatol. 2021 Dec.

Abstract

Background: It is often difficult to accurately predict how a melanoma will progress because melanomas can be so diverse in their genetic and histological makeup.

Objective: We sought to characterize the current state and progression of biomedical markers towards their utilization as prognostic indicators for patients with melanoma.

Methods: A literature search of the research repository databases PubMed and GoogleScholar was conducted using the following inclusion criteria: (1) published within the last 10 years, and (2) use of overall survival, disease progression, or clinical outcome as primary endpoints. Search terms included various permutations of "biomarkers," "prognostic," "immunologic," "serologic," "visual," and "melanoma." Results were evaluated for statistical power, results significance, and experimental design integrity.

Results: The prognostic capabilities of clinical tests for malignant melanoma have made great strides in the last few years, with several serologic and immunohistochemical biomarkers being preliminarily linked to various measures of clinical prognosis. While clinical feasibility of a single sensitive and specific biomarker remains unfeasible, use of select combinations of tested biomarkers remain viable.

Conclusion: Diagnostic and prognostic genetic assays have begun to cross over from research to commercial application, giving physicians additional tools during the early stages of diagnosis to optimize and individualize treatments.

Keywords: Immunologic marker; checkpoint inhibitor; melanoma; screening assay; serum marker.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURES: The authors report no conflicts of interest relevant to the content of this article.

References

    1. Melanoma - Statistics. https://www.cancer.net/cancer-types/melanoma/statistics (2012, June 25). Retrieved from.
    1. Rozeman EA, Dekker TJA, Haanen JBAG, Blank CU. Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives. American Journal of Clinical Dermatology. 2018;19(3):303–317. - PubMed
    1. Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Review of Anticancer Therapy. 2018;18(8):775–784. - PMC - PubMed
    1. Grob JJ, Schadendorf D, Lorigan P. Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. European Journal of Cancer. 2018;91:168–170. - PubMed
    1. Hogan SA, Levesque MP, Cheng PF. Melanoma Immunotherapy: Next-Generation Biomarkers. Frontiers in Oncology. 2018;8:178. - PMC - PubMed

LinkOut - more resources